Novavax - NVAX Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year target prices for Novavax's shares. Their NVAX share price forecasts range from $27.00 to $207.00. On average, they expect the company's stock price to reach $109.25 in the next twelve months. This suggests a possible upside of 561.7% from the stock's current price.
View analysts price targets for NVAX or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the start of the year. Since then, NVAX shares have decreased by 88.5% and is now trading at $16.51.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NVAX earnings forecast.

Novavax, Inc. (NASDAQ:NVAX) posted its earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($2.15) earnings per share for the quarter, missing the consensus estimate of $2.21 by $4.36. The biopharmaceutical company earned $734.58 million during the quarter, compared to analyst estimates of $555.50 million. Novavax had a negative net margin of 71.59% and a negative trailing twelve-month return on equity of 572.54%. The firm's quarterly revenue was up 310.7% compared to the same quarter last year. During the same period last year, the company posted ($4.31) earnings per share.

Novavax shares reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Novavax updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.00 billion, compared to the consensus revenue estimate of $2.04 billion.

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.55%), State Street Corp (4.66%), Credit Suisse AG (1.20%), Renaissance Technologies LLC (1.12%), Coatue Management LLC (0.70%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends.

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $16.51.

Novavax (NASDAQ:NVAX) has a market capitalization of $1.30 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis.

The company employs 1,541 workers across the globe.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.